# Patient-Trial Match Report

*Generated: 2026-01-05 18:31:00*

## Patient Profile

- **Age**: 67
- **Sex**: Male
- **Cancer Type**: pancreatic cancer
- **Biomarkers**: KRAS G12D

**Clinical Description**:
> 67-year-old male with locally advanced pancreatic ductal adenocarcinoma (head of pancreas), KRAS G12D mutated. Not surgical candidate due to SMV encasement. Completed FOLFIRINOX x8 cycles with stable disease, then switched to gemcitabine/nab-paclitaxel due to neuropathy. Now with radiographic progression and rising CA19-9 (2400 -> 8500). Moderate abdominal discomfort, using long-acting opioids. Nutrition supported with pancreatic enzyme replacement. Weight stable past 4 weeks. Seeking novel KRAS-targeted approaches including G12D-specific inhibitors.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 12
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 45
- **LLM scored**: 55

## üü¢ HIGH Likelihood (33 trials)

### [NCT07094204](https://clinicaltrials.gov/study/NCT07094204)

**A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications**

- **Sponsor**: Astellas Pharma Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 95%

**‚úì Supporting Factors:**
- Patient has locally advanced pancreatic ductal adenocarcinoma (PDAC), which is a target condition of the trial.
- Patient has a documented KRAS G12D mutation, which is one of the required biomarkers.
- ECOG performance status is 1, which meets the trial's criteria.
- Patient has received prior standard therapy in the advanced setting, as the trial requires.
- Patient has received two prior lines of systemic therapy (FOLFIRINOX and gemcitabine/nab-paclitaxel), which is within the allowed limits.

**Assessment:**
> The patient has a confirmed diagnosis of pancreatic cancer (the study's interest), appropriate KRAS mutation, and prior treatment that fits the trial's inclusion requirements, indicating a high likelihood of eligibility.

---

### [NCT04887805](https://clinicaltrials.gov/study/NCT04887805)

**Phase II Trial of Lenvatinib-Pembrolizumab Maintenance Therapy in Patients With Advanced Unresectable Pancreatic Cancer**

- **Sponsor**: City of Hope Medical Center
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age: 67
- ECOG status: 1
- Diagnosis of advanced unresectable pancreatic ductal adenocarcinoma (PDA)
- Received more than 16 weeks of prior therapy with stable disease
- No brain metastases
- Confirmed KRAS G12D mutation, seeking novel KRAS-targeted approaches

**? Uncertainties:**
- Laboratory values for organ function (hemoglobin, ANC, platelets, bilirubin, liver enzymes, creatinine, INR, aPTT)

**Assessment:**
> The patient's cancer type matches the study's focus on advanced unresectable pancreatic cancer. The patient has prior therapies and stable disease, which aligns with the trial's eligibility criteria. Additionally, the ECOG status and age are acceptable. However, specific laboratory values are not provided, representing minor uncertainties.

---

### [NCT05141149](https://clinicaltrials.gov/study/NCT05141149)

**A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer**

- **Sponsor**: Prestige Biopharma Limited
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age is 67, which meets the age requirement (‚â• 18 years old)
- ECOG status is 1, which meets the performance status requirement (‚â§ 1)
- Diagnosis of advanced/metastatic pancreatic cancer confirmed
- Patient has a life expectancy of ‚â• 3 months
- No brain metastases present
- Prior therapies include at least one prior line of standard chemotherapy

**Assessment:**
> The patient's cancer type (locally advanced pancreatic ductal adenocarcinoma) matches the trial indication for advanced/metastatic pancreatic cancer, and the patient has received prior therapies which align with trial requirements. All key eligibility criteria are satisfied.

---

### [NCT05535894](https://clinicaltrials.gov/study/NCT05535894)

**Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer**

- **Sponsor**: West Virginia University
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Diagnosis of pancreatic cancer
- Referred for abdominal and/or back pain due to pancreatic cancer
- ECOG status 1

**Assessment:**
> The patient's cancer type matches the study's focus on pancreatic cancer, and the patient has indicated abdominal discomfort, which correlates with the trial's inclusion criteria. Additionally, the ECOG status is acceptable for participation. The patient has prior therapies, which does not disqualify them for this trial since it is aimed at previously treated patients.

---

### [NCT06984562](https://clinicaltrials.gov/study/NCT06984562)

**Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study**

- **Sponsor**: Fox Chase Cancer Center
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histologically confirmed locally advanced pancreatic ductal adenocarcinoma
- Locally advanced unresectable PDA due to SMV encasement
- ECOG status 1

**? Uncertainties:**
- Bone marrow, hepatic, renal function lab values are not provided

**Assessment:**
> The patient's cancer type is a match for the study, as he has locally advanced pancreatic ductal adenocarcinoma, and he is not a surgical candidate due to SMV encasement. His ECOG status is acceptable, and he fits the inclusion criteria regarding treatment prior to radiation therapy (having completed chemotherapy). However, there are uncertainties regarding his organ function lab values.

---

### [NCT01174121](https://clinicaltrials.gov/study/NCT01174121)

**A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age: 67
- Sex: male
- Cancer type: pancreatic cancer
- ECOG status: 1
- Prior therapies: FOLFIRINOX, gemcitabine, nab-paclitaxel
- No brain metastases

**? Uncertainties:**
- Serology test results for HIV, hepatitis B, and hepatitis C not provided
- Full organ function lab results (e.g., ANC, WBC, platelet count, hemoglobin, ALT/AST, creatinine, total bilirubin) not provided

**Assessment:**
> The patient's cancer type (pancreatic cancer) matches the conditions studied in the trial, and the patient is in a previously treated line of therapy, which aligns with the requirements. While some lab results and serologies are awaited, the major criteria supporting eligibility align well with the profile.

---

### [NCT03608631](https://clinicaltrials.gov/study/NCT03608631)

**Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histologically confirmed metastatic pancreatic ductal adenocarcinoma
- Patient has KRAS G12D mutation
- ECOG status is 1
- Completed FOLFIRINOX with stable disease for more than 4 months
- No brain metastases

**? Uncertainties:**
- Absolute neutrophil count (ANC) levels
- Platelet count
- Hemoglobin levels
- Total bilirubin levels
- AST and ALT levels
- Alkaline phosphatase levels
- Creatinine levels

**Assessment:**
> The patient's cancer type matches the trial's indications, and he has the required KRAS G12D mutation. He has also completed sufficient previous treatments with documented stable disease. There are no significant exclusion factors noted, though laboratory values for organ function are not provided.

---

### [NCT04789486](https://clinicaltrials.gov/study/NCT04789486)

**Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma**

- **Sponsor**: Dana-Farber Cancer Institute
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histologically confirmed pancreatic ductal adenocarcinoma
- Locally advanced, unresectable pancreatic cancer determined by clinical criteria
- Completion of at least 3 months of standard induction chemotherapy (FOLFIRINOX and gemcitabine/nab-paclitaxel)
- ECOG status of 1
- No brain metastases

**? Uncertainties:**
- Normal organ and marrow function criteria not provided (e.g., absolute neutrophil count, platelets, liver function tests, creatinine levels)
- Ability to understand and follow the breathing instructions involved in the respiratory gating procedure is unknown
- Need confirmation if the patient has history of allergic reactions attributed to gadolinium-based IV contrast

**Assessment:**
> The patient's cancer type (pancreatic ductal adenocarcinoma) aligns with the trial's indication, and the treatment history meets the criteria of being previously treated. Additional eligibility aspects require verification, especially regarding organ function and procedural capabilities, but overall, the patient appears to be a strong candidate for this trial.

---

### [NCT05786924](https://clinicaltrials.gov/study/NCT05786924)

**A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies**

- **Sponsor**: Institut de Recherches Internationales Servier
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age is 67, which is acceptable for oncology trials
- ECOG status is 1, which is acceptable for most trials
- Cancer type is advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) with KRAS G12D mutation, matching the trial's focus on KRAS mutation-related tumors
- Prior therapies include systemic treatments, aligning with the trial criteria for previously treated patients

**? Uncertainties:**
- Adequate bone marrow and organ function are not explicitly stated in the patient profile
- Weight stability and nutrition support are provided, but specific organ function labs are missing

**Assessment:**
> The patient's diagnosis of pancreatic cancer with a KRAS G12D mutation aligns with the trial's focus. The treatment history implies the patient is eligible as a previously treated candidate. Other criteria are met, though some details about organ function remain unspecified.

---

### [NCT06385925](https://clinicaltrials.gov/study/NCT06385925)

**Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation**

- **Sponsor**: Tyligand Pharmaceuticals (Suzhou) Limited
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has pancreatic cancer which is a type of advanced solid tumor being studied in the trial.
- Patient has KRAS G12D mutation.
- Patient has ECOG status of 1, which is acceptable for the trial.
- Patient has previous treatments that are considered refractory or intolerable to standard treatment.

**? Uncertainties:**
- Adequate cardiac, liver, renal function not provided.

**Assessment:**
> The patient's cancer type matches the trial's focus on KRAS G12D mutant pancreatic cancer, and the treatment history shows prior systemic therapy, which aligns with the trial's criteria for previously treated patients. The only uncertainty pertains to the adequacy of organ function, which is not explicitly confirmed.

---

### [NCT06630325](https://clinicaltrials.gov/study/NCT06630325)

**Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT)**

- **Sponsor**: OHSU Knight Cancer Institute
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has advanced pancreatic cancer, which matches the trial's condition studied.
- ECOG status is 1, which is acceptable for this trial.
- Patient is over 18 years old, meeting the age requirement.
- Patient has documented progression after prior therapies, indicating eligibility for treatment after first-line.
- No brain metastases, consistent with the trial requirements.

**? Uncertainties:**
- Exact results for laboratory values such as absolute neutrophil count, platelets, hemoglobin, creatinine, bilirubin, and liver enzymes are not provided in the profile.

**Assessment:**
> The patient's advanced pancreatic cancer aligns with the trial's focus. He has prior systemic therapies which satisfy the requirement of documented progression after treatment. While some laboratory values are unknown, there is enough information to support a high likelihood of eligibility.

---

### [NCT07023731](https://clinicaltrials.gov/study/NCT07023731)

**A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors**

- **Sponsor**: Arvinas Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histological diagnosis of unresectable pancreatic ductal adenocarcinoma confirmed with KRAS G12D mutation
- Received prior standard-of-care systemic therapy (FOLFIRINOX and gemcitabine/nab-paclitaxel)
- ECOG status of 1
- No active brain metastases
- Has at least one measurable lesion

**Assessment:**
> The patient's cancer type (pancreatic ductal adenocarcinoma) matches the trial criteria, and they have the required KRAS G12D mutation. The patient has been previously treated with standard therapies appropriate for their disease and meets the ECOG performance status requirement. No exclusion criteria apply.

---

### [NCT07020221](https://clinicaltrials.gov/study/NCT07020221)

**A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors**

- **Sponsor**: Verastem, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age: 67 (‚â•18)
- ECOG status: 1 (0 or 1)
- Cancer type: pancreatic cancer matches trial condition
- Biomarker: KRAS G12D mutation present
- Prior therapies: received multiple systemic therapies (FOLFIRINOX, gemcitabine/nab-paclitaxel)
- No brain metastases

**? Uncertainties:**
- Adequate organ function (not explicitly stated)
- Adequate cardiac function (not explicitly stated)

**Assessment:**
> The patient's cancer type matches the trial's focus on KRAS G12D mutant pancreatic cancer. The patient has a relevant treatment history and meets the age and ECOG performance status criteria. While there are uncertainties regarding organ and cardiac function, the absence of brain metastases strengthens eligibility.

---

### [NCT04484909](https://clinicaltrials.gov/study/NCT04484909)

**Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age: 67
- Sex: male
- Cancer type: pancreatic cancer
- ECOG status: 1
- Prior therapies: completed FOLFIRINOX x8 cycles, switched to gemcitabine/nab-paclitaxel
- Brain metastases: none
- Biomarkers: KRAS G12D mutated
- No distant metastases

**Assessment:**
> The patient's cancer type (locally advanced pancreatic cancer) matches the trial's indications. The patient has completed prior treatments, which is acceptable as the trial includes previously treated patients. The ECOG status is appropriate, and the patient has no brain metastases, further supporting eligibility.

---

### [NCT04222413](https://clinicaltrials.gov/study/NCT04222413)

**First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histologically confirmed pancreatic cancer
- ECOG status 1
- Progressed on multiple lines of standard systemic chemotherapy
- No standard therapy option available, as patient is seeking novel KRAS-targeted approaches

**? Uncertainties:**
- Adequate coagulation metrics (INR status not provided)
- Adequate hepatic function metrics (bilirubin, AST, ALT not provided)
- Adequate renal function metrics (creatinine or CrCl not provided)

**Assessment:**
> The patient's cancer type (pancreatic cancer) aligns with the conditions studied in the trial. The patient has also progressed on multiple lines of standard therapy, fitting the eligibility criteria for previously treated patients. While there are uncertainties regarding some organ function metrics, the overall assessment leans towards high eligibility.

---

### [NCT05382559](https://clinicaltrials.gov/study/NCT05382559)

**A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation**

- **Sponsor**: Astellas Pharma Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has locally advanced pancreatic cancer with KRAS G12D mutation.
- Patient has an ECOG status of 1.
- Patient has received prior standard therapy (FOLFIRINOX and gemcitabine/nab-paclitaxel).

**? Uncertainties:**
- Organ function lab values are not provided.
- Recent blood transfusion status is unclear.
- Adverse events from prior therapy are not specified.
- Absence of any active infections is unsaid.

**Assessment:**
> The patient's cancer type (locally advanced pancreatic cancer with KRAS G12D) matches the trial's indication. The patient has also received prior therapies, aligning with the inclusion criteria for previously treated patients. While there are some uncertainties regarding organ function and current health status, the overall profile strongly supports eligibility.

---

### [NCT06179160](https://clinicaltrials.gov/study/NCT06179160)

**A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation**

- **Sponsor**: Incyte Corporation
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has locally advanced pancreatic cancer
- Patient has KRAS G12D mutation
- ECOG status is 1
- Disease progression on prior standard treatment

**Assessment:**
> The patient's cancer type matches the trial focus on solid tumors with KRAS G12D mutation. Additionally, the patient has previously received standard treatment, and their ECOG performance status is acceptable. There are no apparent conflicts or uncertainties in the provided patient information.

---

### [NCT06040541](https://clinicaltrials.gov/study/NCT06040541)

**Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has pancreatic ductal adenocarcinoma (PDAC), which matches the trial conditions studied.
- Patient has a KRAS G12D mutation, which is required for this trial.
- ECOG status is 1, which is acceptable for the trial.
- Patient has received prior therapies and is showing radiographic progression.

**? Uncertainties:**
- Adequate organ function is not confirmed in the patient profile.

**Assessment:**
> The patient's cancer type (pancreatic ductal adenocarcinoma) and KRAS G12D mutation align with the trial's focus. The ECOG status is acceptable, and the patient has received multiple prior treatments as required. The only uncertainty is regarding organ function, which is not explicitly confirmed.

---

### [NCT06227377](https://clinicaltrials.gov/study/NCT06227377)

**A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation**

- **Sponsor**: Quanta Therapeutics
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has pathologically documented locally advanced pancreatic cancer with KRAS G12D mutation.
- Patient has received at least one prior systemic therapy.
- Patient has an ECOG status of 1.

**? Uncertainties:**
- Organ function labs are not provided, creating uncertainty about adequate organ function.

**Assessment:**
> The patient's cancer type matches the trial's indication and the patient's previous therapies satisfy the treatment line requirement. The ECOG performance status is acceptable. However, there is an uncertainty regarding the patient's organ function as specific lab results are not provided.

---

### [NCT06218914](https://clinicaltrials.gov/study/NCT06218914)

**Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors**

- **Sponsor**: AstraZeneca
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has pancreatic adenocarcinoma, which is one of the conditions studied in the trial.
- Patient has KRAS G12D variant mutation, which is specified in the inclusion criteria.
- Patient is 67 years old, which meets the age requirement (‚â•18 years).
- Patient has an ECOG status of 1, fitting within the acceptable range (0-1).
- Patient has advanced solid cancer, specifically unresectable pancreatic cancer.
- Patient has completed previous systemic treatment lines as required.

**? Uncertainties:**
- Patient's HLA type is not provided, which is necessary to confirm eligibility.

**Assessment:**
> The patient has pancreatic adenocarcinoma and meets the necessary inclusion criteria for the trial, including age, ECOG status, and having a KRAS G12D mutation. However, the patient's HLA type is unknown, leaving a minor uncertainty regarding eligibility.

---

### [NCT06586515](https://clinicaltrials.gov/study/NCT06586515)

**A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- histological diagnosis of locally advanced pancreatic ductal adenocarcinoma
- evidence of KRAS G12D mutation
- ECOG performance status of 1
- received prior lines of systemic chemotherapy (FOLFIRINOX, gemcitabine, nab-paclitaxel)

**Assessment:**
> The patient's cancer type (pancreatic ductal adenocarcinoma) matches the trial's indication. The patient has the required KRAS G12D mutation, is within the acceptable ECOG status, and has received prior systemic therapy, making him a suitable candidate for this trial.

---

### [NCT06447662](https://clinicaltrials.gov/study/NCT06447662)

**A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histological diagnosis of advanced, unresectable pancreatic ductal adenocarcinoma
- ECOG status of 1
- Presence of KRAS mutation (G12D)
- Completed multiple lines of standard therapy and progressed radiographically

**Assessment:**
> The patient's cancer type of pancreatic ductal adenocarcinoma matches the trial conditions. The patient has an ECOG status of 1 and carries the required KRAS G12D mutation, and has progressed after standard therapies, meeting both the treatment line and biomarker criteria.

---

### [NCT06364696](https://clinicaltrials.gov/study/NCT06364696)

**An Open-label Phase 1 Study of ASP4396 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation**

- **Sponsor**: Astellas Pharma Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has locally advanced pancreatic ductal adenocarcinoma with KRAS G12D mutation.
- Patient has received prior standard therapy (FOLFIRINOX and gemcitabine/nab-paclitaxel).
- Patient has ECOG performance status of 1.

**? Uncertainties:**
- Patient's organ function (not explicitly stated).

**Assessment:**
> The patient's cancer type matches the trial's indication, they have the required KRAS mutation and have completed prior therapies, with a suitable ECOG status. The only uncertainty revolves around confirming their organ function.

---

### [NCT06607185](https://clinicaltrials.gov/study/NCT06607185)

**A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- ECOG status of 1
- Local advanced pancreatic ductal adenocarcinoma diagnosis
- Biomarker KRAS G12D mutation is present

**Assessment:**
> The patient's cancer type matches the trial's focus on pancreatic ductal adenocarcinoma. The treatment history indicates prior therapies, which aligns with the study allowing previously treated patients. The patient has the required KRAS G12D mutation, and an ECOG status within the acceptable range. No significant conflicts or uncertainties are present.

---

### [NCT06619587](https://clinicaltrials.gov/study/NCT06619587)

**A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation**

- **Sponsor**: Genentech, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has locally advanced pancreatic ductal adenocarcinoma which matches the trial condition of advanced solid tumor.
- Patient has a KRAS G12D mutation which is required by the trial.
- ECOG status is 1 which is acceptable for trial eligibility.

**Assessment:**
> The patient's cancer type and molecular profile match the trial's criteria, and their ECOG status is acceptable. The patient has prior therapies, but the trial does not specify that it is limited to treatment-naive patients, thus supporting eligibility.

---

### [NCT06411691](https://clinicaltrials.gov/study/NCT06411691)

**Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma**

- **Sponsor**: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has pancreatic cancer, which is being studied in the trial.
- Patient has KRAS G12D mutation matching the trial's criteria for KRAS mutations.
- Patient has measurable disease per RECIST 1.1 (rising CA19-9 and recent progression).
- Patient has received 4-6 months of FOLFIRINOX for 1st line treatment of metastatic unresectable PDAC.

**? Uncertainties:**
- Adequate organ and marrow function test results not provided.

**Assessment:**
> The patient's cancer type (pancreatic cancer) matches the trial, and they have the required KRAS G12D mutation. They also have a history of receiving appropriate first-line treatment. No major conflicts are present, but laboratory function tests are not specified.

---

### [NCT06797336](https://clinicaltrials.gov/study/NCT06797336)

**A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors**

- **Sponsor**: PAQ Therapeutics, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histologically or cytologically confirmed advanced or metastatic solid malignancy
- Pathologically documented KRAS G12D mutation identified
- ECOG Performance Status of 1

**Assessment:**
> The patient's cancer type, pancreatic cancer with a KRAS G12D mutation, matches the trial's target indication. The patient has advanced disease, an ECOG status of 1, and has a documented KRAS mutation, fulfilling the major eligibility criteria. No conflicts or uncertainties were identified.

---

### [NCT06910657](https://clinicaltrials.gov/study/NCT06910657)

**A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors**

- **Sponsor**: ViroMissile, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age: 67
- ECOG status: 1
- Cancer type: pancreatic cancer
- Prior therapies: FOLFIRINOX, gemcitabine, nab-paclitaxel (indicates previous treatment)

**? Uncertainties:**
- Measurable disease status per RECIST v1.1 (not explicitly stated but assumed from radiographic progression)
- Adequate organ and bone marrow function (not explicitly stated)

**Assessment:**
> The patient's cancer type is pancreatic cancer, which matches the trial criteria. The patient is previously treated and has an ECOG status of 1, fulfilling the trial's inclusion criteria. There are no major conflicts, and although there are a couple of uncertainties regarding organ function and measurable disease, overall eligibility is strong.

---

### [NCT06917079](https://clinicaltrials.gov/study/NCT06917079)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has pancreatic ductal adenocarcinoma (PDAC) with KRAS G12D mutation.
- ECOG status is 1, which is acceptable.
- Patient has measurable disease by radiographic criteria.

**Assessment:**
> The patient has a confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC) with the KRAS G12D mutation, which matches the conditions studied in the trial. Additionally, the patient‚Äôs ECOG performance status is eligible, and there is evidence of measurable disease. The patient's prior therapies were appropriate, and there are no noted conflicts with the inclusion criteria.

---

### [NCT07090499](https://clinicaltrials.gov/study/NCT07090499)

**A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Advanced pancreatic adenocarcinoma as cancer type
- ECOG status 1
- 2 lines of prior systemic therapy (FOLFIRINOX and gemcitabine/nab-paclitaxel)
- No brain metastases

**Assessment:**
> The patient's cancer type of pancreatic adenocarcinoma matches the study conditions. They have the necessary ECOG status (1) and fit the included treatment line criteria, having had 2 prior therapies. There are no conflicts or uncertainties present.

---

### [NCT07207707](https://clinicaltrials.gov/study/NCT07207707)

**A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation**

- **Sponsor**: Kumquat Biosciences Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Pathologically confirmed locally advanced pancreatic ductal adenocarcinoma (PDAC) with KRAS G12D mutation
- Patient has progressed on prior standard systemic therapies including FOLFIRINOX and gemcitabine/nab-paclitaxel
- ECOG status is 1, which is acceptable for trials

**? Uncertainties:**
- Adequate organ function is not explicitly confirmed
- Measurable disease status according to RECIST v1.1 is not confirmed

**Assessment:**
> The patient has a confirmed diagnosis of pancreatic cancer with the required KRAS G12D mutation and meets the treatment line criteria, having progressed on previous therapy. Some organ function details are missing, but the major eligibility factors align.

---

### [NCT06922591](https://clinicaltrials.gov/study/NCT06922591)

**A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation**

- **Sponsor**: Tango Therapeutics, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 80%

**‚úì Supporting Factors:**
- ECOG PS of 1
- Has received prior standard therapy (FOLFIRINOX, gemcitabine/nab-paclitaxel)
- Has a tumor with a RAS mutation (KRAS G12D)
- Age is 67, which is ‚â•18

**? Uncertainties:**
- Loss of MTAP protein or bi-allelic deletion of the MTAP gene is not provided
- Evidence of measurable disease based on RECIST v1.1 is not provided
- Adequate organ function is not specified

**Assessment:**
> The patient's cancer type (pancreatic cancer) matches the trial's indication, and he has previously received standard therapy, which is compatible with the trial's eligibility. There are some uncertainties regarding the loss of MTAP, measurable disease, and organ function, but overall he appears eligible.

---

### [NCT03257033](https://clinicaltrials.gov/study/NCT03257033)

**Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer**

- **Sponsor**: RenovoRx
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 75%

**‚úì Supporting Factors:**
- Patient has locally advanced pancreatic ductal adenocarcinoma.
- ECOG status is 1.
- Patient is over 18 years old.
- No brain metastases present.

**‚úó Potential Conflicts:**
- Patient does not meet exclusion criteria for prior treatment as they have received multiple lines of therapy.

**? Uncertainties:**
- Adequate laboratory values are not provided (e.g., ANC, platelet count, hemoglobin, creatinine, AST, ALT, bilirubin levels).

**Assessment:**
> The patient's cancer type matches the trial criteria as he has locally advanced pancreatic cancer. Although he has had prior therapy, the trial does not explicitly state it is only for treatment-naive patients, so he may still qualify under the prior treatment criteria. However, lab values are missing, which introduces some uncertainty.

---

## üü° MEDIUM Likelihood (1 trials)

### [NCT07033689](https://clinicaltrials.gov/study/NCT07033689)

**Open-label, Non-randomized, Single-center Study Investigating the Feasibility, Safety, Tolerability and Efficacy of Suizenji in Unresectable Pancreatic Ductal Adenocarcinoma Patients**

- **Sponsor**: SONIRE Therapeutics Inc.
- **Phase**: Early Phase 1
- **Status**: Not yet recruiting
- **Confidence**: 50%

**‚úì Supporting Factors:**
- Patient is 67 years old and meets the age requirement (‚â• 18 years)
- Patient has histologically diagnosed pancreatic ductal adenocarcinoma (PDAC)
- Patient has an ECOG Performance Status of 1
- Patient has locally advanced disease, which is considered unresectable
- Patient has adequate life expectancy of ‚â• 3 months
- Patient has no brain metastases

**‚úó Potential Conflicts:**
- Patient has prior systemic therapy (FOLFIRINOX, gemcitabine, nab-paclitaxel), which contradicts eligibility criterion requiring newly diagnosed unresectable disease without prior therapies.
- The primary tumor site must be accessible to HIFU treatment and visualized on transabdominal ultrasonography, which is not confirmed in patient data.

**? Uncertainties:**
- Exact organ function lab results (neutrophils, platelets, hemoglobin, creatinine, AST, ALT, bilirubin) are not provided and must be confirmed to check for adequate organ function.
- The requirement regarding the accessibility of the primary tumor to HIFU treatment is unclear.

**Assessment:**
> The patient has a match for the disease type since they have diagnosed PDAC. However, they are not treatment-naive due to previous therapies, which does not align with the trial criteria for newly diagnosed unresectable disease. Additionally, there is uncertainty related to organ function and tumor accessibility for treatment.

---

## üü† LOW Likelihood (1 trials)

### [NCT03551951](https://clinicaltrials.gov/study/NCT03551951)

**Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening**

- **Sponsor**: University of Missouri-Columbia
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 30%

**‚úì Supporting Factors:**
- Patient has a diagnosis of pancreatic cancer, which is included in the trial conditions.

**‚úó Potential Conflicts:**
- Patient has prior systemic therapies (FOLFIRINOX, gemcitabine, nab-paclitaxel) which indicates they are not treatment-naive, but the trial's treatment line is unclear.

**? Uncertainties:**
- It is unclear from the trial description whether it is specifically aimed at first-line or subsequent treatments.

**Assessment:**
> The patient has pancreatic cancer, which matches the trial's condition. However, the presence of prior therapies creates uncertainty about their eligibility regarding treatment lines. The trial's stance on treatment-naive versus previously treated patients remains ambiguous, thus leading to a determination of LOW match likelihood.

---

## Excluded (65 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT04657068](https://clinicaltrials.gov/study/NCT04657068) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04939610](https://clinicaltrials.gov/study/NCT04939610) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05688215](https://clinicaltrials.gov/study/NCT05688215) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05985655](https://clinicaltrials.gov/study/NCT05985655) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05997056](https://clinicaltrials.gov/study/NCT05997056) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06048484](https://clinicaltrials.gov/study/NCT06048484) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06445062](https://clinicaltrials.gov/study/NCT06445062) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06790602](https://clinicaltrials.gov/study/NCT06790602) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06821997](https://clinicaltrials.gov/study/NCT06821997) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06989437](https://clinicaltrials.gov/study/NCT06989437) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07043270](https://clinicaltrials.gov/study/NCT07043270) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07145255](https://clinicaltrials.gov/study/NCT07145255) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07202247](https://clinicaltrials.gov/study/NCT07202247) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07223047](https://clinicaltrials.gov/study/NCT07223047) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07282912](https://clinicaltrials.gov/study/NCT07282912) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00001532](https://clinicaltrials.gov/study/NCT00001532) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02417740](https://clinicaltrials.gov/study/NCT02417740) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03568630](https://clinicaltrials.gov/study/NCT03568630) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03740256](https://clinicaltrials.gov/study/NCT03740256) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04361708](https://clinicaltrials.gov/study/NCT04361708) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 25 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT04820179](https://clinicaltrials.gov/study/NCT04820179) | University of Arizon | Patient has received prior treatments (FOLFIRINOX and gemcitabine/nab-paclitaxel), while the trial requires patients with metastatic pancreatic cancer who are refractory or intolerant to prior treatment. |
| [NCT05836870](https://clinicaltrials.gov/study/NCT05836870) | M.D. Anderson Cancer | Patient has locally advanced pancreatic cancer which is not classified as resectable/borderline resectable (T1-3, N0-2, M0) as required by the trial. |
| [NCT06747845](https://clinicaltrials.gov/study/NCT06747845) | Abramson Cancer Cent | Patient has previously received multiple lines of therapy including FOLFIRINOX and gemcitabine/nab-paclitaxel, while the trial specifically targets patients who have received 8-12 cycles of first-line therapy with stable disease or better. |
| [NCT06906562](https://clinicaltrials.gov/study/NCT06906562) | Sameek Roychowdhury | Patient has KRAS G12D mutation, which conflicts with Cohort 1 that excludes patients with concurrent KRAS mutations. |
| [NCT05086250](https://clinicaltrials.gov/study/NCT05086250) | Cedars-Sinai Medical | Patient has been treated previously with FOLFIRINOX and gemcitabine/nab-paclitaxel which is against the trial's requirement for patients within 12 weeks of receiving cancer targeted treatment. |
| [NCT06698458](https://clinicaltrials.gov/study/NCT06698458) | Alpha Tau Medical LT | Patient has prior systemic therapy (FOLFIRINOX, gemcitabine, nab-paclitaxel) but the trial requires treatment-na√Øve patients. |
| [NCT03745326](https://clinicaltrials.gov/study/NCT03745326) | National Cancer Inst | Patient is 67 years old, which exceeds the maximum age limit of 72 years. |
| [NCT02012699](https://clinicaltrials.gov/study/NCT02012699) | University of Nebras | Patient has previously treated pancreatic cancer, while the trial may require treatment-naive patients. |
| [NCT04970056](https://clinicaltrials.gov/study/NCT04970056) | Arbor Research Colla | Patient has pancreatic cancer, which may not fit eligibility criteria focusing on early detection and not treatment of invasive cancer. |
| [NCT04157127](https://clinicaltrials.gov/study/NCT04157127) | Diakonos Oncology Co | Patient has locally advanced pancreatic cancer which is deemed unresectable, while the trial requires potentially resectable or borderline resectable pancreatic cancer. |
| [NCT05984602](https://clinicaltrials.gov/study/NCT05984602) | NYU Langone Health | Patient has previously received multiple treatments (FOLFIRINOX, gemcitabine, nab-paclitaxel), which contradicts the trial's requirement for treatment-naive patients. |
| [NCT02757859](https://clinicaltrials.gov/study/NCT02757859) | Sidney Kimmel Cancer | The patient does not have a surgical indication for pancreatectomy due to being a non-surgical candidate. |
| [NCT05296421](https://clinicaltrials.gov/study/NCT05296421) | Rutgers, The State U | Patient has prior systemic therapy (FOLFIRINOX and gemcitabine/nab-paclitaxel), while the trial requires either treatment-naive patients or those with neoadjuvant chemotherapy but no prior treatment. |
| [NCT06182072](https://clinicaltrials.gov/study/NCT06182072) | ProDa BioTech, LLC | Patient has prior exposure to gemcitabine and nab-paclitaxel, which is an exclusion criteria |
| [NCT06271291](https://clinicaltrials.gov/study/NCT06271291) | Mayo Clinic | Patient has pancreatic cancer (PDAC), but the trial is for individuals without pancreatic cancer. |
| [NCT06360354](https://clinicaltrials.gov/study/NCT06360354) | Amgen | The patient does not have homozygous MTAP-deletion which is required for both subprotocols. |
| [NCT06454383](https://clinicaltrials.gov/study/NCT06454383) | City of Hope Medical | Patient has prior therapies (FOLFIRINOX, gemcitabine, nab-paclitaxel) while the trial requires treatment-naive patients. |
| [NCT06162221](https://clinicaltrials.gov/study/NCT06162221) | Revolution Medicines | Patient has KRAS G12D mutation, but trial requires KRAS G12C or RAS-mutated NSCLC. This is a clear mismatch. |
| [NCT05254184](https://clinicaltrials.gov/study/NCT05254184) | Sidney Kimmel Compre | Patient has pancreatic cancer, while the trial is for patients with non-small cell lung cancer. |
| [NCT07270237](https://clinicaltrials.gov/study/NCT07270237) | Memorial Sloan Kette | The trial does not study pancreatic ductal adenocarcinoma as a treatment measure; it focuses on ultrasound imaging methods and requires patients for endoscopic ultrasound-guided biopsies for those already diagnosed. |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12D | manual | 1.0 |
| KRASG12D | manual | 0.9 |
| KRAS-G12D | manual | 0.9 |
| pancreatic cancer | manual | 1.0 |
| KRAS G12D pancreatic cancer | manual | 1.0 |
| KRAS G12D pancreatic ductal adenocarcinoma | llm | 0.9 |
| KRAS G12D PDAC | llm | 0.9 |
| pancreatic ductal adenocarcinoma | llm | 0.8 |
| PDAC | llm | 0.8 |
| KRAS p.G12D | llm | 0.9 |
| KRASp.G12D | llm | 0.8 |
| KRAS-p.G12D | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Cardiac status/QTc interval** - relevant for trials with cardiotoxicity risk
